Royalty Pharma PLC (NAS:RPRX)
$ 28.09 0.12 (0.43%) Market Cap: 12.67 Bil Enterprise Value: 17.27 Bil PE Ratio: 15.87 PB Ratio: 1.95 GF Score: 79/100

Royalty Pharma PLC at JPMorgan Healthcare Conference Transcript

Jan 09, 2024 / 05:00PM GMT
Release Date Price: $28.33 (+1.32%)
Christopher Schott
JPMorgan Chase & Co, Research Division - Senior Analyst

Good morning, everybody. I'm Chris Schott at JPMorgan, and it's my pleasure to be introducing Royalty Pharma this morning. In our view, this is a really unique business model, helping finance innovation across the whole biopharma space.

From the company, we have Pablo Legorreta, the company's Founder and CEO, and then we're going to have a Q&A session with the broader management team.

With that, Pablo, Happy New Year, and thanks for joining us today.

Pablo Legorreta
Royalty Pharma plc - Founder, Chairman of the Board & CEO

Happy New Year to you, Chris, and thank you very much for the invitation to present at JPMorgan. I was actually reflecting last night and this morning that I've actually been coming to this conference, I think, for about 25 years. I started Royalty Pharma 27 years ago. And the thought that came to my mind is that the first 21, 22 years, I was coming to the conference, sitting very much like many of you in the audience to try to learn

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot